Posted by Michael Wonder on 09 Nov 2020
FDA grants rare paediatric disease designation to AMO Pharma for AMO-02 for treatment of congenital myotonic dystrophy
9 November 2020 - Designation qualifies AMO-02 for fast track review and AMO Pharma to receive a priority review voucher pending marketing approval.
AMO Pharma today announced that the U.S. FDA has granted a rare paediatric disease designation to AMO Pharma for AMO-02, the company's investigational therapy in development for the treatment of congenital myotonic dystrophy.
